Table 1.
Botulinum toxin A in thyroid eye disease-related strabismus
| Study | Sample size (n) | Follow-up | Preoperative deviation | Duration of TED before injection | BTA dose and mean injection per patient | Outcomes |
|---|---|---|---|---|---|---|
| Dunn et al.20 Retrospective |
8 | Average 9.8 months | Average 19.5 | Average 5.4 (1-8 months) One case 2 years |
1.25-5 unit 2.1 injection/patient |
Average deviation at last follow-up 2.25 PD (range, 0-6 PD) |
| Akbari et al.25 Prospective interventional case series |
20 | 26.8±2.8 months | - | Up to 3 years | 25 units (Dysport) 3.2±1.5 injection/patient |
Success rate 55% |
| Gair et al.26 Retrospective | 65 | 1-8 years | Hypotrpia 23 (3-60) ET 32 (4-65) |
0.5-30 years | Dysport (6.5 pg/0.1 ml) 1-11 injection/patient | 4.5% were maintained on repeated injection 78.5% poor response 4.5% declined further BTA Short duration and mild degree of strabismus have a chance of long-term benefit |
| Wu et al.27 Retrospective |
33 | 17.0±12.77 months | Horizontal 35±20.3 Vertical 33±17.27 |
- | 8.16±1.43 units 6.48±2 injection/patient |
15 cases were cured, 12 cases were partially improved, 6 cases had poor response |
| Granet et al.28 Retrospective |
22 | Up to 12 months | - | - | 5-15 units (Botox) | 59% patients benefited from BTA (success rate 37%, partial success 22%) |
PD: Prism diopter, TED: Thyroid eye disease, BTA: Botulinum toxin A, ET: Esotropia